F. Sciurba, R. Wise, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Ensifentrine是一种新型的双磷酸二酯酶(PDE) 3和4抑制剂,在Ensifentrine治疗COPD的增强-1期3期试验中,可改善肺功能、症状、生活质量并降低恶化率和风险","authors":"F. Sciurba, R. Wise, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"22 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD\",\"authors\":\"F. Sciurba, R. Wise, T. Rheault, T. Bengtsson, K. Rickard\",\"doi\":\"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":332705,\"journal\":{\"name\":\"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD\",\"volume\":\"22 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD